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Mohs micrographic surgery is a method for removal of 
non-melanoma skin cancer in thin layers, allowing frozen-
section examination of all peripheral and deep margins. 
Subsequent tissue layers are removed as dictated by micro-
scopic examination, allowing for maximal sparing of normal 
tissue. This method offers cure rates significantly higher than 
excision or other modalities. Mohs micrographic surgery is 
the method of choice for removal of large, recurrent or 
incompletely excised skin cancers or for tumors located in 
regions of high recurrence. 
Nationally, it is estimated that more than 500,000 new 
cases of non-melanoma skin cancer (primarily basal cell car-
cinoma (BCC) and squamous cell carcinoma (SCC)) are diag-
nosed each year' . With exposure to the sun being the most 
important risk factor, Hawaii can be expected to have a high 
incidence rate. Indeed, skin cancer rates on Kauai, observed 
prospectively for 5 years, appear disproportionately high to 
the rest of the nation in unpublished data. 
The majority of these cancers may be effectively treated 
with as compared curettage and electrodesiccation, excision, 
cryosurgery and irradiation. However, certain subsets of these 
carry with them higher recurrence rates and present a more 
demanding therapeutic challenge. Mobs micrographic surgery 
has emerged as the most reliable and effective method for 
removing the more difficult non-melanoma skin cancers. 
Mohs surgery offers maximal normal tissue preservation as 
well as the lowest recurrence rates of all current modalities 
for the treatment of non-melanoma skin cancer at high risk 
for recurrence. 
Historical background 
Frederic Mohs developed the technique originally in the 
1930s at the University of Wisconsin. He applied a fixative 
paste of zinc chloride and stibnite directly to a patient' s skin 
cancer, the paste was allowed to fix the skin overnight, and 
then the fixed skin was removed (without bleeding or need for 
local anesthesia) the following day. The tissue was processed 
using horizontal permanent sections after carefully mapping, 
grossing and color-coding the tissue to maintain strict orienta-
tion. The tissue was examined by Mobs for remaining tumor, 
which, when found, was drawn on the map as a positive area. 
The process was then repeated daily, removing tissue only in 
the remaining positive areas until the patient was tumor-free. 
This technique, called chemosurgery, was published in 1941 2 
and was found in this and in subsequent studies to result in 
extraordinarily low recurrence rates, in the range of 1% or 
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lower for primary BCC2.3.4.s and 2% to 4% for recurrent 
BCC2.6.7.s. 
In light of the extraordinarily low recurrence rates as a 
result of chemosurgery, some investigators began to modify 
the technique. Tromovitch and Stegman of the University of 
California at San Francisco found that fresh tissue, rather than 
fixed, removed from the patient and processed as frozen sec-
tions yielded equally good results as the fixed technique9·10•11 • 
In addition, the fresh tissue modification offered 3 advan-
tages: 1) the pain from in situ tissue fixation was avoided'; 2) 
multiple stages (layers of tissue removal) could be performed 
in one day, shortening considerably the time needed; and 3) 
the post-fixation tissue slough was avoided, allowing for 
immediate reconstruction. 
Because of these distinct advantages, the fresh tissue tech-
nique has virtually replaced the fixed technique. The term 
"chemosurgery" is of historic value at present. With universal 
acceptance of the fresh tissue modification, the technique 
was renamed "Mohs micrographic surgery" in 1981'3·'', by 
the American College of Micrographic Surgery and 
Cutaneous Oncology. 
Indications 
Mohs surgery is an ideal method for precisely removing 
non-melanoma skin cancers that are more likely to recur, and 
those whose clinical margins are unclear or inaccurate. In 
general, there are 5 main predictors of skin cancers that will 
have a higher recurrence rate: 1) An aggressive histologic sub-
type; 2) regions of the human body with a higher recurrence 
TABLE 1 
Aggressive Histologic Subtypes 
M rpheaft rm or fibro ing BCC 
AdeniodBCC 
Infiltrative BCC 
Micronodular BC 
Metatypi al BC (Ba 
Anapl ti cc 
Acanth lytic C 
uamou CA) 
Dermatofibroma arc rna P~' tuberan 
Mi racy tic adnexal A 
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rate; 3) recurrent tumors; 4) clinical size 
> 2 em; and 5) incompletely excised 
tumors. 
Aggressive histology refers to sever-
al subtypes of non-melanoma skin can-
cer that routinely have microscopic 
extensions beyond clinically apparent 
margins. The most commonly encoun-
tered aggressive subtypes for which 
Mohs micrographic surgery is appropri-
ate therapy are listed in Table 1. 
Subclinical extensions of morpheaform 
BCC in one study' 5 averaged 7.2 mm 
beyond clinically apparent margins. 
Figure 1 shows a preoperative clinical 
Figure 1: Preoperative appearance of 
morpheaform BCC 
appearance of a patient with mor-
pheaform BCC. The postoperative 
appearance, after Mohs sections were 
shown to be tumor-free, is shown in 
Figure 2. 
Location of a non-melanoma skin 
cancer is somewhat predictive of likeli-
hood of recurrence. Certain locations of 
BCC of the head and neck result in 
higher-than-expected recurrence rates. 
These locations are depicted in Figure 
3'6 and include the nose (especially tip, 
ala, dorsum), nasolabial fold, columella, 
philtrum, periorbital areas, pre- and 
postauricular areas, temple , and the 
helix of the ear''·'8• sec recurs more fre-
quently and is more likely to metasta-
size when located on the ear, lip or in a 
burn scar' 9 • In addition to the higher 
recurrence rate of central facial and 
periauricular lesions, these areas also 
command a great deal of functional 
and/or cosmetic importance. Maximal 
sparing of normal tissue, as well as high 
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MOHS MICROGRAPHIC SURGERY: A SYNOPSIS (continuedfrompage 135) 
cure rates may be best achieved with Mobs surgery in these areas. 
Recurrent non-melanoma skin cancers pose a challenge to 
any modality of treatment. Recurrent tumors may track along 
old scar tissue and thus grow in an irregular fashion, produc-
ing subclinical extensions. Mobs surgery affords the highest 
cure rate compared with any other modality for recurrent BCC 
and SCC 19•20 and is the treatment of choice for recurrent 
lesions. 
Tumor size (preoperative) of> 2 em carries an increased 
recurrence rate due to greater subclinical extensions21 • In addi-
tion, SCC > 2 em also has an increased metastatic potentiaP. 
Mobs reported a cure rate of 99.8% for BCC < 2 em'. This rate 
decreased to 98.6% in tumors> 2 em. By comparison, a study 
from NYU18 calculated the overall 5-year cure rate in primary 
BCC treated with excision to be 90.7%. The cure rate dropped 
to 87.9% in tumors >1.5 em and 76.9% in tumors> 3 em. 
Incompletely excised tumors (recent excision with positive 
margins histologically) pose a high risk of recurrence if no 
further therapy is given. Pascal22 found that BCC treated by 
excision and found to have tumor present within I high-power 
field of the surgical margin showed a 12% recurrence rate if 
merely observed clinically. This rate increased to 35% when 
Figure 3: 
Areas with 
high risk of 
BCC 
recurrence* 
Figure 2: 
Postoperative 
appearance of 
patient in 
Figure 1 
the tumor actually involved the surgical margin. Positive mar-
gins indicate an extension of tumor that was not otherwise 
apparent clinically. The most definitive method of ensuring 
that the margins are clear is subsequent treatment by Mobs. 
There are several other situations in which Mobs is favored 
as a method of treatment. A BCC or SCC with perineural 
spread carries an increased risk of recurrence. BCC in a patient 
with basal cell nevus syndrome may be aggressive, making 
tissue-sparing especially important; such cancers also are more 
numerous. Some less common skin malignancies also are 
amenable to Mobs surgery, such as verrucous carcinoma, seba-
ceous carcinoma, eccrine carcinoma (especially microcystic 
adnexal carcinoma), and dermatofibroma sarcoma protuber-
ans. Some Mobs surgeons have applied this method of 
removal to melanoma; however, its use in pigmented lesions is 
not universally accepted and remains controversial. 
Preparation 
A patient referred for Mobs surgery should have had a prior 
biopsy with report and have slides available for review by the 
Mobs surgeon. A preoperative visit is ideal as the patient's 
medical history can be reviewed and any special requirements 
on the part of the patient (such as discontinuing anticoagulants, 
arranging for anticipated repair with a reconstructive surgeon, 
initiation of any prophylactic antibiotics) can be planned. The 
eTll!Tl Over 
eStamEdges 
::;,}~ 
~ 
Figure 4: Schematic of Mohs micrographic surgical technique* 
*Reprinted with the permission from the September 1983 issue of Archives ofDermato1ogy, vo1119:761-773, Copyright 1983, American Medical Association. 
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lesion size may be determined on an initial visit and, if it is 
large, the case can be scheduled appropriately. Lesion size on 
clinical inspection, however, is not always accurately predictive 
of actual microscopic extent of tumor. 
Technique 
The procedure usually is performed in an outpatient set-
ting, generally in a clinic, using local anesthesia. The tumor is 
ftrst debulked, removing obvious cancer cells with a curette or 
scalpel. This process is outlined in Figure 4. A thin layer of 
tissue is then removed with a scalpel, beveling the edges to 45 
degrees. Orientation is strictly maintained throughout the pro-
cedure. Several small cuts (scores) are made in the specimen 
and at the surgical site for alignment. Hemostasis is achieved 
with electrocoagulation and/or suture ligation, the patient is 
bandaged and is free to relax and wait in the waiting room 
while the tissue is being processed. The skin is mapped and 
divided into pieces of appropriate size by a technician (usual-
ly no larger than 1 em) for frozen sectioning. Contrasting dye 
is used to mark cut edges to assist in orientation. The speci-
men is flattened on a glass slide to bring the epidermal edge 
into the same plane as the deep margin. The tissue is frozen in 
this position in a cryostat. The skin is then cut into horizontal 
sections on a cryostat, taking care to align the tissue chuck 
properly to ensure a complete section. Meticulous flattening 
of the tissue and positioning of the tissue chuck in the cryostat 
are essential in producing suitable horizontal sections. For this 
reason, cryostat models that do not allow flexible positioning of 
the tissue chuck are not appropriate for this procedure. The 
frozen sections are then stained, coverslipped and presented to 
the Mohs surgeon for interpretation. The slides are examined by 
the surgeon for evidence of remaining tumor and areas noted to 
be positive for tumor are clearly marked on the tissue map. 
The patient then returns to the treatment room for removal 
of additional tissue. By comparing the tissue map to the oper-
ative site, only tissue in the positive area will be removed, 
sparing tissue observed to be tumor-free. The process is 
repeated until all the sections are found to be negative. Of 
prime importance is the fact that the Mohs surgeon acts as 
both the surgeon and the pathologist. The orientation of the 
specimen in this procedure can be lost or obscured when more 
than one person performs both roles. 
Unlike routine pathologic examination of excisions, the 
entire peripheral and deep margins are examined in Mohs sec-
tions. Traditional histologic exams of excisions, even wide 
excisions, only sample the margins in several areas. 
Statements of "margins free of tumor" on pathology reports 
do not imply that all of the margins were examined. 
In cases of aggressive spread of tumor into vital structures 
such as ear canals, orbits, bone, major nerve trunks, it may be 
necessary to work in conjunction with physicians from other 
specialties. In such cases, an ENT surgeon, for example, may 
be guided by the Mobs surgeon to an area that remains positive 
for tumor in an ear canal or nasal bone. This may be done in an 
operating room setting under general or IV anesthesia. 
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Sometimes it is necessary to process a tissue layer in per-
manent sections often necessitating a l-day wait for results in 
cases where bone is involved (requiring decalcification) or in 
tumors found difficult to discern on frozen section. 
Recurrence rates 
A thorough review of the literature and a weighted com-
parison of recurrence rates from all modalities was done in 1 
study for primary BCC23 • Looking at 5-year follow-up of pri-
mary BCC recurrence, surgical excision showed a 10.1% 
recurrence rate, curettage and electrodesiccation (C&E) a 
7.7% recurrence, radiation therapy a rate of 8.7% and 
cryotherapy a rate of 7.5 %. Some caution is advised in con-
sidering rates in C&E and cryotherapy because large, high-
risk lesions may not have been included in many of these 
studies. 
Overall all non-Mohs modalities had a recurrence rate of 
8.7%. At 5-years' follow-up, removal by Mohs surgery result-
ed in a recurrence rate of 1%. 
A similar study on recurrent BCC20 with 5- year follow-up 
also was observed. Surgical excision showed a recurrence rate 
of 17.4%, radiation therapy a rate of 9.8% and C&E a rate of 
40%. Cryotherapy had a short-term recurrence rate of 13%, 
but there was no data on cryotherapy 5-year follow-up. 
All non-Mohs modalities had an overall recurrence rate of 
19.9%. Mohs surgery showed a weighted average of 5.6% 
recurrence rate 5-years later. Therefore, according to these 
studies, non-Mohs modalities have a recurrence rate 8 times 
that of Mohs in primary BCC and 4 times that of Mohs in 
recurrent BCC. 
In primary SCC of the skin, a similar study examined the 
5-year recurrence rate using the following therapeutic meth-
ods19: Surgical excision had a local recurrence rate of 8.1 %, 
curettage and electrodesiccation a rate of 3. 7, and radiation 
therapy a rate of 10%. Again, there may have been some bias 
in selection with respect to the C&E modality, as this method 
is not used very often in large, high-risk SCC. Overall non-
Mohs methods show a 5-year recurrence rate of 7.9%. 
Mohs surgery was found to have a 3.1% recurrence rate 
after 5 years. In locally recurrent SCC, surgical excision had a 
5-year recurrence rate of 23%, compared with a 10% recur-
rence rate with Mohs surgery. 
Several factors increase risk of recurrence or metastasis in 
sec, including the degree of differentiation, the size of the 
tumor, its depth and site. In SCC of ::;; 2 em, surgical excision 
affords a cure rate of 83.5%, but when > 2 em, the cure rate 
drops to 58.3%. Comparison with Mohs shows 98.1% and 
74.8% cure rates respectively. Surgical excision of well-dif-
ferentiated sec offers a cure rate of 81.0%, but this drops to 
46.4% for poorly differentiated SCC. By comparison, Mohs 
cure rates are 97% and 67.4%, respectively. Mohs surgery 
affords the patient with sec a significantly increased cure 
rate, even in cases at high risk for local recurrence and metas-
tasis. Lower cure rates for Mohs surgery in poorly differenti-
ated sec may reflect the tumor's propensity for early 
metastasis; it is also more difficult to define this tumor on 
frozen section. 
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The pros and cons 
As described above, Mohs micrographic surgery offers sig-
nificantly increased cure rates in cases of BCC and SCC as 
compared with other methods. In addition, maximum sparing 
of healthy tissue is achieved; this is of prime importance when 
cancers occur on the face and ears. The vast majority of Mohs 
surgical procedures are done using local anesthesia in an out-
patient setting, avoiding the risk of general anesthesia and 
operating room charges. Long-term cost is less, as recurrence 
is much less likely, thus avoiding subsequent procedures. 
A relative disadvantage is that special training is necessary 
to perform Mohs micrographic surgery. Typically, fellowship 
programs require 1 to 2 years' training after a dermatology 
residency (or after an ENT or plastic surgery residency). A 
laboratory setting that incorporates a cryostat and staining 
hood also is necessary. It is essential that an expert technician 
be available who has had special training in preparing Mohs 
sections. 
Mohs surgery is certainly more time consuming than other 
modalities, the time spent in processing often runs from a half 
hour to 1 hour per stage. Very large tumors may require 
numerous sections and will take several hours to process. This 
fact may deter some patients who may be unable or unwilling 
to wait for the tissue to be processed. The short-term costs of 
the procedure also are greater than those of other previously 
mentioned methods. 
Conclusion 
Mohs micrographic surgery offers the highest cure rates at 
present for non-melanoma skin cancer. It is the method of 
choice for patients at high risk of recurrence of non-melanoma 
skin cancer: Those with large, recurrent, incompletely excised 
or aggressive tumors or with tumors in areas of high potential 
for recurrence. Practitioners who evaluate patients with non-
melanoma skin cancer are well-advised to be familiar with 
this method in order to give proper informed consent to their 
patients about the choice of therapeutic methods. 
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